FCPA and Anti-Corruption for the Life Sciences Industry

Tuesday, May 14 to Wednesday, May 15, 2013

ONE UN New York Hotel, New York, NY

The government has made it clear that life sciences companies are under a microscope, and the FCPA and anti-corruption prosecutions will keep coming.  Attend the leading anti-corruption conference dedicated the unique issues facing life sciences companies and gain  advanced industry-specific strategies to bulletproof already-robust FCPA compliance plans.

In 2012, federal and international enforcement authorities have aggressively continued their pursuit of biopharmaceutical and medical device companies for FCPA and anti-corruption violations, resulting in high profile investigations and record-breaking fines and settlements.  In response to the challenges facing biopharmaceutical and medical device companies in this daunting climate as the life sciences industry sweep continues, the 7th Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry provides a forum for the key players- top prosecutors, preeminent corporate counsel, and leading FCPA practitioners- to come together to give you a specific action plan to bolster your anti-corruption compliance regime and combat the next wave of FCPA allegations.  

Attendees of this event will:

• Hear directly from multiple panels of current and former prosecutors who will share inside insights into government enforcement priorities and share tips on putting together a gold-standard FCPA and anti-corruption compliance program tailored to the specific business needs of life sciences companies doing research and development internationally
• Walk away with a same-day action plan to conduct a risk-based assessment of FCPA exposure to build a life sciences specific  anti-bribery compliance program based on examples from the guidance and from life sciences settlements 
• Benchmark best compliance practices against leading companies such as Allergan, Johnson & Johnson, Medicis Pharmaceuticals, Medtronic, Millennium: The Takeda Oncology Company, Pfizer Inc. and many more who will share strategies on intensive training, auditing, monitoring, and internal investigations in order to proactively prevent against the corruption schemes commonly used in the life sciences industry 
• Take away cutting-edge knowledge to minimize global anti-corruption risks and FCPA violations in key areas including screening and monitoring foreign third parties and HCPs, conducting international clinical trials, mergers & acquisition due diligence, and travel and hospitality
  

Prosecutors are using all the tools at their disposal to ensure that FCPA and anti-corruption violations by medical device and biopharmaceutical companies are brought to the light and punished. Do not miss your chance to be part of the most comprehensive, industry-tailored forum to formulate innovative solutions to proactively protect your company before, during, and after the government comes knocking.

Brochure

- click image for pdf -

- Actions -

- Share -

Location:
ONE UN New York Hotel
New York, NY